This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Soga, S. Articles by Akinaga, S. Search for Related Content PubMed PubMed Citation Articles by Soga, S. Articles by Akinaga, S.

KF25706, a Novel Oxime Derivative of Radicicol, Exhibits in Vivo Antitumor Activity via Selective Depletion of Hsp90 Binding Signaling Molecules

Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Shizuoka-ken 411-8731, Japan [S.S., Y.S., K.A., H.N., T.A., Y.I., C.M., T.T., S.A.]; and Medicine Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 [L.M.N., T.W.S.]

Radicicol, a macrocyclic antifungal antibiotic, has been shown to bind to the heat shock protein 90 (Hsp90) chaperone, interfering with its function. Hsp90 family chaperones have been shown to associate with several signaling molecules and play an essential role in signal transduction, which is important for tumor cell growth. Because radicicol lacks antitumor activity in vivo in experimental animal models, we examined the antitumor activity of a novel radicicol oxime derivative, radicicol 6-oxime (KF25706), on human tumor cell growth both in vitro and in vivo. KF25706 showed potent antiproliferative activities against various human tumor cell lines in vitro and inhibited v-src- and K-ras-activated signaling as well as radicicol. In addition, Hsp90 family chaperone-associated proteins, such as p185^erbB2, Raf-1, cyclin-dependent kinase 4, and mutant p53, were depleted by KF25706 at a dose comparable to that required for antiproliferative activity. KF25706 was also shown to compete with geldanamycin for binding to Hsp90. KF29163, which is an inactive derivative of radicicol, was less potent both in p185^erbB2 depletion and Hsp90 binding. More importantly, KF25706 showed significant growth-inhibitory activity against human breast carcinoma MX-1 cells transplanted into nude mice at a dose of 100 mg/kg twice daily for five consecutive i.v. injections. KF25706 was also shown to possess antitumor activity against human breast carcinoma MCF-7, colon carcinoma DLD-1, and vulval carcinoma A431 cell lines in vivo in an animal model. Finally, we confirmed the depletion of Hsp90-associated signaling molecules (Raf-1 and cyclin-dependent kinase 4) with ex vivo Western blotting analysis using MX-1 xenografts. In agreement with in vivo antitumor activity, KF25706 depleted Hsp90-associated molecules in vivo, whereas KF29163 and radicicol did not show this activity in vivo. Taken together, these results suggest that antitumor activity of KF25706 may be mediated, at least in part, by binding to Hsp90 family proteins and destabilization of Hsp90-associated signaling molecules.

This article has been cited by other articles:

				R. K. Allan, D. Mok, B. K. Ward, and T. Ratajczak Modulation of Chaperone Function and Cochaperone Interaction by Novobiocin in the C-terminal Domain of Hsp90: EVIDENCE THAT COUMARIN ANTIBIOTICS DISRUPT Hsp90 DIMERIZATION J. Biol. Chem., March 17, 2006; 281(11): 7161 - 7171. [Abstract] [Full Text] [PDF]

				J. T. Price, J. M.W. Quinn, N. A. Sims, J. Vieusseux, K. Waldeck, S. E. Docherty, D. Myers, A. Nakamura, M. C. Waltham, M. T. Gillespie, et al. The Heat Shock Protein 90 Inhibitor, 17-Allylamino-17-demethoxygeldanamycin, Enhances Osteoclast Formation and Potentiates Bone Metastasis of a Human Breast Cancer Cell Line Cancer Res., June 1, 2005; 65(11): 4929 - 4938. [Abstract] [Full Text] [PDF]

				N. Shimada, T. Ishii, T. Imada, K. Takaba, Y. Sasaki, K. Maruyama-Takahashi, Y. Maekawa-Tokuda, H. Kusaka, S. Akinaga, A. Tanaka, et al. A Neutralizing Anti-Fibroblast Growth Factor 8 Monoclonal Antibody Shows Potent Antitumor Activity against Androgen-Dependent Mouse Mammary Tumors In vivo Clin. Cancer Res., May 15, 2005; 11(10): 3897 - 3904. [Abstract] [Full Text] [PDF]

				D. Gadelle, C. Bocs, M. Graille, and P. Forterre Inhibition of archaeal growth and DNA topoisomerase VI activities by the Hsp90 inhibitor radicicol Nucleic Acids Res., April 22, 2005; 33(7): 2310 - 2317. [Abstract] [Full Text] [PDF]

				T. M. Griffin, T. V. Valdez, and R. Mestril Radicicol activates heat shock protein expression and cardioprotection in neonatal rat cardiomyocytes Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1081 - H1088. [Abstract] [Full Text] [PDF]

				R. Bagatell and L. Whitesell Altered Hsp90 function in cancer: A unique therapeutic opportunity Mol. Cancer Ther., August 1, 2004; 3(8): 1021 - 1030. [Abstract] [Full Text] [PDF]

				H.-R. Li, E. I. Shagisultanova, K. Yamashita, Z. Piao, M. Perucho, and S. R. Malkhosyan Hypersensitivity of Tumor Cell Lines with Microsatellite Instability to DNA Double Strand Break Producing Chemotherapeutic Agent Bleomycin Cancer Res., July 15, 2004; 64(14): 4760 - 4767. [Abstract] [Full Text] [PDF]

				D. G. Hay, K. Sathasivam, S. Tobaben, B. Stahl, M. Marber, R. Mestril, A. Mahal, D. L. Smith, B. Woodman, and G. P. Bates Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach Hum. Mol. Genet., July 1, 2004; 13(13): 1389 - 1405. [Abstract] [Full Text] [PDF]

				F. Ravandi, M. Talpaz, and Z. Estrov Modulation of Cellular Signaling Pathways: Prospects for Targeted Therapy in Hematological Malignancies Clin. Cancer Res., February 1, 2003; 9(2): 535 - 550. [Abstract] [Full Text] [PDF]

				N. Fujita, S. Sato, A. Ishida, and T. Tsuruo Involvement of Hsp90 in Signaling and Stability of 3-Phosphoinositide-dependent Kinase-1 J. Biol. Chem., March 15, 2002; 277(12): 10346 - 10353. [Abstract] [Full Text] [PDF]

				P. Bonvini, T. Gastaldi, B. Falini, and A. Rosolen Nucleophosmin-Anaplastic Lymphoma Kinase (NPM-ALK), a Novel Hsp90-Client Tyrosine Kinase: Down-Regulation of NPM-ALK Expression and Tyrosine Phosphorylation in ALK+ CD30+ Lymphoma Cells by the Hsp90 Antagonist 17-Allylamino,17-demethoxygeldanamycin Cancer Res., March 1, 2002; 62(5): 1559 - 1566. [Abstract] [Full Text] [PDF]

				S. A. Pilon, M. P. Piechocki, and W.-Z. Wei Vaccination with Cytoplasmic ErbB-2 DNA Protects Mice from Mammary Tumor Growth Without Anti-ErbB-2 Antibody J. Immunol., September 15, 2001; 167(6): 3201 - 3206. [Abstract] [Full Text] [PDF]

				Y. Shiotsu, L. M. Neckers, I. Wortman, W. G. An, T. W. Schulte, S. Soga, C. Murakata, T. Tamaoki, and S. Akinaga Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G1 phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex Blood, September 15, 2000; 96(6): 2284 - 2291. [Abstract] [Full Text] [PDF]

				R. Bagatell, G. D. Paine-Murrieta, C. W. Taylor, E. J. Pulcini, S. Akinaga, I. J. Benjamin, and L. Whitesell Induction of a Heat Shock Factor 1-dependent Stress Response Alters the Cytotoxic Activity of Hsp90-binding Agents Clin. Cancer Res., August 1, 2000; 6(8): 3312 - 3318. [Abstract] [Full Text]

				S. W. Ki, K. Ishigami, T. Kitahara, K. Kasahara, M. Yoshida, and S. Horinouchi Radicicol Binds and Inhibits Mammalian ATP Citrate Lyase J. Biol. Chem., December 8, 2000; 275(50): 39231 - 39236. [Abstract] [Full Text] [PDF]